Article

Bausch & Lomb building on silicone hydrogel demand

Rochester, NY—Increased demand for Bausch & Lomb's PureVision SVS contact lens has the company potentially shifting gears away from its PureVision Toric lens, which was to be introduced in the United States this summer.

Bausch & Lomb said it was "reassessing" the launch plan in light of "overwhelming demand" for the single-vision spherical lens-fueled by a faster-than-expected shift toward silicone hydrogel lenses-and said it wanted to capitalize on the trend. However, the company said overall production of the PureVision line was ahead of schedule and assured it would launch the PureVision Toric lens in the United States as soon as it had built sufficient inventory to meet the anticipated demand.

Meanwhile, the company said its SofLens66 Toric lens continues to grow at double-digit rates, giving the company flexibility with its PureVision Toric launch plans.

The flurry of excitement is bound to continue as the company progresses with a major expansion of its main research and development center in Rochester, NY. The $35 million project-$25 million for new construction and $10 million for renovations, equipment, and machinery-will include up to 200 new research jobs over the next 2 years. The building will see a new two-story, 75,000-square-foot glass-and-brick wing for laboratories and offices, and will offer room for a future 25,000-square-foot addition. Completion is slated for early 2007.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Two-year data of bio-interventional cyclodialysis with scleral allograft with Leon W. Herndon Jr, MD
(Image credit: Ophthalmology Times) AGS 2025: Aqueous humor outflow improvement after excimer laser trabeculostomy with Clemens Strohmaier, PhD
(Image credit: Ophthalmology Times) Thomas W. Samuelson, MD, shares clinical perspectives on DSLT, SLT, and glaucoma management
Image credit: Ophthalmology Times; Dean McGee Eye Institute resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
Image credit: Ophthalmology Times; EnVision Summit 2025: Sonia H. Yoo, MD, shares what to expect from the cataract and refractive agenda
© 2025 MJH Life Sciences

All rights reserved.